Skip to main content
SpringerLink
Log in

Heart rate in ischemic heart disease. The innovation of ivabradine: More than pure heart rate reduction

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

A wealth of data suggests that heart rate (HR) is an independent predictor of cardiovascular and all-cause mortality in men and women of all ages with and without cardiovascular disease. Data gathered from clinical trials suggest that HR reduction is an important mechanism of benefit of HR-lowering drugs. A high HR has direct detrimental effects not only on myocardial ischemia but also on the progression of atherosclerosis, ventricular arrhythmias, and on left ventricular function. The risk increases with HR >60 b.p.m. Ivabradine, a drug that slows HR though an effect on the If channels, has been approved for the control of myocardial ischemia in patients with coronary artery disease intolerant to beta-blockers. More recently, the indication of ivabradine has been extended for use in association with beta-blockers in patients with coronary artery disease. The effects of ivabradine on myocardial ischemia are greater than those predicted by pure HR reduction with beta-blockers, suggesting additional mechanisms of action.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Palatini P, Thijs L, Staessen JA, et al. Predictive power of clinical and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med. 2002;162:2313–2321.

    Article  PubMed  Google Scholar 

  2. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967–974.

    Article  PubMed  Google Scholar 

  3. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;352:1951–1958.

    Article  CAS  PubMed  Google Scholar 

  4. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens. 2004;26:637–644.

    Article  CAS  PubMed  Google Scholar 

  5. Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs. 2006;66:133–144.

    Article  CAS  PubMed  Google Scholar 

  6. Fox KM. Exercise heart rate/ST segment relation. Perfect predictor of coronary disease. Br Heart J. 1982;48:309–310.

    Article  CAS  PubMed  Google Scholar 

  7. Perret-Guillaume C, Joly L, Benetos A. Heart rate as a risk factor for cardiovascular disease. Prog Cardiovasc Dis. 2009;52:6–10.

    Article  PubMed  Google Scholar 

  8. Beddhu S, Nigwekar SU, Ma X, Greene T. Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease. Nephrol Dial Transplant. 2009;24:2482–2488.

    Article  CAS  PubMed  Google Scholar 

  9. Longenecker JC, Zubaid M, Johny KV, et al. Association of low heart rate variability with atherosclerotic cardiovascular disease in hemodialysis patients. Med Princ Pract. 2009;18:85–92.

    Article  CAS  PubMed  Google Scholar 

  10. Reil JC, Böhm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol. 2007;96:585–592.

    Article  PubMed  Google Scholar 

  11. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817–821.

    Article  PubMed  Google Scholar 

  12. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. BEAUTIFUL investigators. Ivabradine for patients with stable coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–816.

    Article  CAS  PubMed  Google Scholar 

  13. Ferrari R, Ford I, Fox K, Steg PG, Tendera M. BEAUTIFUL study group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction — baseline characteristics of the study population. Cardiology. 2008;110:271–282.

    Article  CAS  PubMed  Google Scholar 

  14. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986;57:43F–49F.

    Article  CAS  PubMed  Google Scholar 

  15. Gundersen T, Grottum P, Pedersen T, Kjekshus JK. Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest. Am J Cardiol. 1986;58:20–24.

    Article  CAS  PubMed  Google Scholar 

  16. Boissel JP, Leizorovicz A, Picolet H, Peyrieux JC. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol. 1990;66:251–260.

    Article  CAS  PubMed  Google Scholar 

  17. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40:1589–1595.

    Article  PubMed  Google Scholar 

  18. Heller DA, Ahern FM, Kozak M. Changes in rates of beta-blocker use between 1994 and 1997 among elderly survivors of acute myocardial infarction. Am Heart J. 2000;140:663–671.

    Article  CAS  PubMed  Google Scholar 

  19. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20:764–771.

    Article  CAS  PubMed  Google Scholar 

  20. Ryan AA. Medication compliance and older people: a review of literature. Int J Nursing Stud. 1999;36:153–162.

    Article  CAS  Google Scholar 

  21. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme — a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464–474.

    Article  CAS  PubMed  Google Scholar 

  22. Lechat P, Escolano P, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation. 1997;96:2197–2205.

    CAS  PubMed  Google Scholar 

  23. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007.

    Article  Google Scholar 

  24. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658.

    Article  CAS  PubMed  Google Scholar 

  25. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428–1433.

    CAS  PubMed  Google Scholar 

  26. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and betablocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26:2259–2268.

    Article  CAS  PubMed  Google Scholar 

  27. Gullestad L, Wikstrand J, Deedwania P, et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol. 2005;45:252–259.

    Article  PubMed  Google Scholar 

  28. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group. Circulation. 1990;82:1962–1972.

    CAS  PubMed  Google Scholar 

  29. Andrews TC, Fenton T, Toyosaki N. Subsets of ambulatory myocardial ischemia based on heart rate activity: Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation. 1993;88:92–100.

    CAS  PubMed  Google Scholar 

  30. Botha P, Parry G, Dark JH, Macgowan GA. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. J Heart Lung Transplant. 2009;28:676–682.

    Article  PubMed  Google Scholar 

  31. Tanaka N, Nozawa T, Yasumura Y, Futaki F, Hiramori K, Suga H. Heart-rate-proportional oxygen consumption for constant cardiac work in dog heart. Jpn J Physiol. 1990;40:503–521.

    Article  CAS  PubMed  Google Scholar 

  32. Sambuceti G, Marzilli M, Marraccini P, et al. Coronary vasoconstriction during myocardial ischemia induced by rises in metabolic demand in patients with coronary artery disease. Circulation. 1997;95:2652–2659.

    CAS  PubMed  Google Scholar 

  33. Reynolds R, Calzadilla SV, Lee RV. Spontaneous heart rate, propranolol, and ischaemia-induced ventricular fibrillation in the dog. Cardiovasc Res. 1978;12:653–658.

    Article  CAS  PubMed  Google Scholar 

  34. Panza JA, Diodati JG, Callahan TS, Epstein SE, Quyyumi AA. Role of increases in heart rate in determining the occurrence and frequency of yocardial ischemia during daily life in patients with coronary artery disease. J Am Coll Cardiol. 1992;20:1092–1098.

    Article  CAS  PubMed  Google Scholar 

  35. Pratt CM, McMahon CP, Goldstein S, et al. Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). Am J Cardiol. 1996;77:1302–1309.

    Article  CAS  PubMed  Google Scholar 

  36. Chapter 31: Treatment of myocardial ischemia. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11e. Brunton LL, editor-inchief. Lazo JS and Parker KL, associate editors. The McGraw-Hill Companies, Inc.; 2006.

  37. Rochon PA, Anderson GA, Tu JV, et al. Use of beta-blocker therapy in older patients after acute myocardial infarction in Ontario. Can Med Assoc J. 1999;161:1403–1408.

    CAS  Google Scholar 

  38. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;45:438–444.

    Article  Google Scholar 

  39. Gislason GH. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27:1153–1158.

    Article  CAS  PubMed  Google Scholar 

  40. Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341–1381.

    Article  PubMed  Google Scholar 

  41. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total Ischaemic Burden European trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J. 1996;17:96–103.

    CAS  PubMed  Google Scholar 

  42. Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. Coron Artery Dis. 2002;13:427–436.

    Article  PubMed  Google Scholar 

  43. van der Vring JA, Daniels MC, Holwerda NJ, et al. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Br J Clin Pharmacol. 1999;47:493–498.

    Article  Google Scholar 

  44. Knight CJ, Fox KM. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators. Am J Cardiol. 1998;81:133–136.

    Article  CAS  PubMed  Google Scholar 

  45. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent S16257 on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol. 1996;118:1051–1057.

    CAS  PubMed  Google Scholar 

  46. Borer JS. Drug insight: If inhibitors as specific heartrate- reducing agents. Nat Clin Pract Cardiovasc Med. 2004;1:103–109.

    Article  CAS  PubMed  Google Scholar 

  47. DiFrancesco D. Characterization of single pacemaker channels in cardiac sino-atrial node cells. Nature. 1986;324:470–173.

    Article  CAS  PubMed  Google Scholar 

  48. DiFrancesco D. The contribution of the ‘pacemaker’ current (If) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol (Lond). 1991;434:23–40.

    CAS  Google Scholar 

  49. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64:1757–1765.

    Article  CAS  PubMed  Google Scholar 

  50. Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine a novel I(f) inhibitor lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149–155.

    Article  CAS  PubMed  Google Scholar 

  51. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary and hemodynamic effects of S16257 a new bradycardic agent in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659–666.

    CAS  PubMed  Google Scholar 

  52. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, doubleblind, multicentered, placebo-controlled trial. Circulation. 2003;107:817–823.

    Article  PubMed  Google Scholar 

  53. de Silva R, Fox KM. Angina: ivabradine for treatment of stable angina pectoris. Nat Rev Cardiol. 2009;6:329–330.

    Article  PubMed  CAS  Google Scholar 

  54. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529–2536.

    Article  CAS  PubMed  Google Scholar 

  55. Tardif JC, Ponikowski P, Kahan T. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-bblocker therapy: a 4-month, randomized, placebo-controlled rial. Eur Heart J. 2009;30:5540–548.

    Article  CAS  Google Scholar 

  56. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev. 2005;(4):CD003614.

Download references

Author information

Authors and Affiliations

  1. IRCCS San Raffaele Pisana, Roma, Italy

    Giuseppe M. C. Rosano, Cristiana Vitale & Maurizio Volterrani

  2. San Raffaele Sulmona, Sulmona, Italy

    Giuseppe M. C. Rosano

  3. Department of Medical Sciences, IRCCS San Raffaele Roma, Via della Pisana, 235, 00163, Roma, Italy

    Giuseppe M. C. Rosano

Authors
  1. Giuseppe M. C. Rosano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristiana Vitale
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maurizio Volterrani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe M. C. Rosano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosano, G.M.C., Vitale, C. & Volterrani, M. Heart rate in ischemic heart disease. The innovation of ivabradine: More than pure heart rate reduction. Adv Therapy 27, 202–210 (2010). https://doi.org/10.1007/s12325-010-0030-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0030-9

Keywords

Search

Navigation